Back

19 August 2025

The ITA reports that Kurash athlete Erkin Kozokov accepted a 3 year ban for his anti-doping rule violation

The International Testing Agency (ITA), on behalf of the International Kurash Association (IKA), reports that Uzbek kurash athlete Erkin Kozokov has accepted a three-year sanction after testing positive for the prohibited substance meldonium.

¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athlete will have the right to accept the proposed consequences. If the athlete refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 of the IKA anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed an IKA/ITA decision.

² A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a sample the presence of a prohibited substance or its metabolites or markers or evidence of the use of a prohibited method.

³ Article 10.8.1 of the IKA ADR (and World Anti-Doping Code) provides for a one-year reduction for certain ADRVs based on early admission and acceptance of sanction. This applies where an athlete after being notified by IKA/ITA of a potential ADRV that carries an asserted period of Ineligibility of four (4) or more years, admits the violation and accepts the asserted period of Ineligibility no later than twenty (20) days after receiving notice of an ADRV charge. Where the athlete receives the one-year reduction under Article 10.8.1, no further reduction in the period of Ineligibility is allowed.

Share

Cookie Policy & Privacy Notice

We use cookies on our website to personalize content, to analyze traffic on our website to provide social media features. We share your data with our analytics partners and social media content providers. Find out more

The privacy policy can be accessed here

Your current state: Consent rejected.


Accept Reject Read More